查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984174

多癌种筛检市场：按检测类型、癌症类型、技术、支付方式、应用和最终用户划分－2026-2032年全球市场预测

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，多癌筛检市场价值将达到 6.3087 亿美元，到 2026 年将成长至 8.2284 亿美元，到 2032 年将达到 43.7542 亿美元，年复合成长率为 31.87%。

主要市场统计数据
基准年 2025 6.3087亿美元
预计年份：2026年 8.2284亿美元
预测年份 2032 4,375,420,000 美元
复合年增长率 (%) 31.87%

本文全面概述了多癌种筛检技术的进步如何改变临床实践、研究重点以及诊断和护理路径中的相关人员合作。

分子生物学、生物资讯学和检体采集技术的进步正推动多筛检领域从充满前景的实验性探索走向临床和研究领域的实际应用。新的诊断方法透过扩大微创检体的组织范围，重塑了检测模式，从而再形成了临床工作流程和病患照护路径。因此，参与诊断开发、医疗服务和政策制定的相关人员正在重新评估早期检测、长期监测和循证医学证据生成等方面的优先事项，以支持临床应用。

技术、临床和支付方的进步如何重新定义多癌种筛检创新领域的发展重点和部署路径？

技术变革、数据整合以及报销理念的转变正在推动多癌症种筛检领域发生一系列颠覆性变化。在技​​术层面，液态生物检体、高通量定序和多重检测的创新正在拓展可检测分析物的范围，并降低非侵入性取样的门槛。这些技术进步正在促成先进生物资讯流程的建立，从而提高讯号检测的准确性并降低假阳性噪声，最终产生更多临床实用结果。

该评估旨在评估美国关税政策的变化如何影响诊断产业相关人员在供应链韧性、筹资策略和製造本地化方面的决策。

关税政策和贸易措施的变化将对用于多癌种筛检的试剂、仪器和客製化检测组件的全球供应链产生重大影响。在美国，关税体系的变化正在影响定序试剂、质谱耗材和专用硬体等关键投入品的到货成本，进而影响检查室和诊断开发人员的采购偏好。这些成本压力促使他们更加关注国内采购、策略供应商合作以及库存管理，以确保检测服务的连续性。

透过综合細項分析，揭示测试类型、目标癌症、技术、支付来源、应用和最终用户如何共同影响其采用和临床效用。

細項分析突显了技术方法、临床标靶、支付模式和最终用户群的多样性，这些因素共同塑造了多癌种筛检的路径。根据检测类型，目前的检测方案涵盖了从针对特定基因组区域的基因panel检测到经认证实验室提供的客製化实验室自建检测（LDT），甚至包括液态生物检体——一种利用循环血液中分析物质的微创采样方法。根据癌症类型，目前的筛检涵盖了已建立的靶点，例如乳癌和结直肠癌；骨髓恶性肿瘤，例如白血病；高负担适应症，例如肺癌；广泛且特异性的多器官癌症检测模式；以及器官特异性靶点，例如前列腺癌。

区域比较分析突显了法律规范、支付模式和医疗保健基础设施如何在世界各地造成不同的采用路径。

区域趋势对多筛检计画的实施路径、监管预期和支付方参与度有显着影响。在美洲，成熟的医疗基础设施、活跃的私人保险市场和强大的转化研究网络，为商业性试点计画和经营模式的快速推进创造了有利环境。同时，监管监督和报销讨论的重点在于证明其临床效用并将其整合到临床流程中。在欧洲、中东和非洲，监管协调的努力、多样化的报销环境和不同的医疗服务体系，都要求采用适应性强的循证策略、本地化的卫生经济学模型以及有针对性的相关人员参与，以确保计画的成功实施。

协作、平台差异化和循证定位如何塑造诊断开发公司和检测实验室的竞争策略和商业化路径。

多癌种筛检领域的竞争格局呈现出多元化的特点，既有成熟的诊断公司，也有专业的临床实验室，还有追求差异化科学方法的敏捷生物技术Start-Ups。许多成熟公司正在拓展检测项目组合，并加强与临床网路的合作，以检验更广泛筛检应用的适用性。同时，专业实验室正在整合工作流程并建立认证体系，以支援内部自建检测（LDT）的快速迭代。Start-Ups倾向于专注于独特的生物标记平台、创新的生物资讯技术或检体收集方面的创新，以应对灵敏度、特异性或易用性方面的特定挑战。

为开发人员、测试实验室和医疗保健系统提供切实可行的、基于证据的建议，以加速多癌种筛检的可靠实施和营运弹性。

产业领导者可以透过以下方式加速负责任地推广多癌症种筛检：将产品开发与明确的临床应用案例结合，优先考虑分析的严谨性，并儘早与保险公司和医疗服务提供者合作。首先，制定有针对性的临床路径，明确如何处理阳性筛检结果、必要的确诊步骤以及如何协调后续照护。清晰界定后续行动有助于增强临床效用的论证。其次，投资于不同检体类型和人群的分析有效性和可重复性，以减少变异性并增强临床医生的信心。第三，儘早与保险公司展开对话，建构反映实际照护路径和病人历程的卫生经济模型，为报销谈判奠定基础。

我们采用严格的混合方法研究框架检验了我们在多筛检的发现，该框架结合了专家访谈、同行评审的证据、监管检验和资料三角验证。

本研究途径结合了多方面的证据收集、专家检验和迭代整合，以得出平衡且可操作的见解。主要研究包括对临床医生、检查室管理人员、卫生经济学家和保险公司进行结构化访谈，以了解临床实践中的营运限制、证据预期和决策因素。次要研究则利用同行评审文献、临床试验註册数据、监管申报文件以及卫生技术评估机构发布的公共指南，揭示技术能力和政策趋势。资料三角测量法用于调整不同观点，并识别不同资讯来源中的一致讯号。

总之，综合分析强调，证据的一致性、操作准备以及多方相关人员之间的合作是负责任地实施多癌症种筛检的先决条件。

多癌种筛检正处于转折点，技术成熟度、临床整合需求以及支付方观点的转变共同塑造其未来的发展方向。儘管技术进步使得更广泛、更微创的检测成为可能，但永续推广应用仍需有可验证的临床路径、可互通的报告系统以及一致的报销机制。相关人员致力于明确应用场景定义、在不同人群中进行充分检验并与医疗网络开展务实合作的利益相关者，将更有能力将创新转化为可衡量的临床获益。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按检测类型分類的多癌症种筛检市场

  • 基因检测
  • 实验室开发的测试
  • 液态生物检体

第九章：按癌症类型分類的多癌症种筛检市场

  • 乳癌
  • 结肠癌
  • 白血病
  • 肺癌
  • 特异性多重器官癌
  • 摄护腺癌

第十章：多癌种筛检市场：依技术划分

  • 质谱分析
  • 微阵列
  • 次世代定序
  • 聚合酵素链锁反应

第十一章：按支付方式分類的多癌症种筛检市场

  • 政府补贴
  • 自费
  • 私人医疗保险

第十二章：多癌种筛检市场：依应用领域划分

  • 诊断筛检
    • 早期检测
    • 风险评估
  • 预后
    • 病患监测
    • 治疗方法方案
    • 治疗效果评估
  • 出于研究目的
    • 生物标誌物的发现
    • 基因研究

第十三章：多癌种筛检市场：依最终用户划分

  • 门诊手术中心
  • 诊断中心
  • 医院
  • 研究机构
  • 专科诊所

第十四章：多重癌症筛检市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：多癌种筛检市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：多重癌症筛检市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国多癌症种筛检市场

第十八章：中国多癌症种筛检市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 630.87 million in 2025 and is projected to grow to USD 822.84 million in 2026, with a CAGR of 31.87%, reaching USD 4,375.42 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 630.87 million
Estimated Year [2026] USD 822.84 million
Forecast Year [2032] USD 4,375.42 million
CAGR (%) 31.87%

A compelling overview of how multicancer screening advances are shifting clinical practice, research priorities, and stakeholder collaboration across diagnostics and care pathways

The field of multicancer screening is evolving from experimental promise to pragmatic integration within clinical and research settings, driven by converging advances in molecular biology, bioinformatics, and sample collection technologies. Emerging diagnostic modalities are reframing detection paradigms by offering broader tissue coverage from minimally invasive samples, thereby reshaping clinical workflows and patient pathways. As a result, stakeholders across diagnostics development, healthcare delivery, and policy are reevaluating priorities around early detection, longitudinal monitoring, and evidence generation to sustain clinical adoption.

Clinical laboratories and developers are responding to both scientific and operational pressures: they must balance analytical sensitivity and specificity with throughput, cost, and regulatory compliance. Concurrently, payers and health systems are seeking clearer proof of clinical utility and actionable pathways to integrate positive findings into care. In this environment, translational research and pragmatic trials are emerging as critical bridges between biomarker discovery and routine use, helping to define appropriate use cases, referral networks, and pathway economics that enable responsible scale-up. Consequently, organizations that invest now in robust clinical validation, interoperability, and stakeholder alignment stand to accelerate credible adoption and long-term impact.

How converging technological, clinical, and payer evolutions are redefining development priorities and adoption pathways in multicancer screening innovation

Transformations in technology, data integration, and reimbursement thinking are producing a set of disruptive shifts across the multicancer screening landscape. On the technology front, innovations in liquid biopsy, high-throughput sequencing, and multiplexed assays are expanding the range of detectable analytes and lowering the barrier to noninvasive sampling. These technical gains are accompanied by enhanced bioinformatic pipelines that improve signal detection and reduce false positive noise, enabling more clinically actionable outputs.

At the systems level, there is a move toward integrated care models that link screening results to standardized diagnostic follow-up and treatment pathways. This integration is facilitated by interoperable data standards and electronic health record connectivity that allow screening outcomes to trigger timely clinical responses. Simultaneously, payer discussions are evolving from unitary reimbursement for single-disease tests toward value frameworks that consider longitudinal benefit and downstream care coordination. As a result, stakeholders are recalibrating product development strategies, clinical evidence plans, and commercialization roadmaps to align with these transformative shifts and to secure sustainable clinical and commercial pathways.

Assessing how shifting US tariff policies are influencing supply chain resilience, procurement strategies, and manufacturing localization decisions for diagnostic stakeholders

Tariff policy changes and trade measures can exert meaningful influence on global supply chains for reagents, instruments, and bespoke assay components used in multicancer screening. In the United States, shifts in tariff regimes affect the landed cost of critical inputs such as sequencing reagents, mass spectrometry consumables, and specialized hardware, which in turn influence procurement preferences among laboratories and diagnostic developers. These cost pressures encourage greater attention to domestic sourcing, strategic supplier partnerships, and inventory management practices to maintain continuity of testing services.

Beyond cost considerations, tariffs can accelerate strategic decisions about manufacturing footprint and localization of critical production steps, prompting firms to evaluate regionalized supply chains and nearshoring options. For some organizations, this translates into increased investments in domestic contract manufacturing, secondary sourcing contracts, and supplier qualification programs to mitigate exposure. In parallel, procurement teams and laboratory operators are intensifying scenario planning to absorb short-term pricing volatility while preserving assay performance and regulatory compliance. Ultimately, tariff dynamics serve as both an operational stress test and a catalyst for supply chain resilience strategies that align with long-term clinical service objectives.

Integrated segmentation insights that reveal how test type, cancer target, technology, payment source, application, and end user collectively shape adoption and clinical utility

Segmentation analysis highlights the diversity of technological approaches, clinical targets, payment models, and end users that shape multicancer screening pathways. Based on test type, contemporary offerings range from gene panel approaches that target defined genomic regions to laboratory developed tests that are tailored within certified labs, and to liquid biopsy methods that leverage circulating analytes for minimally invasive sampling. Based on cancer type, the screening landscape spans established targets such as breast cancer and colorectal cancer, hematologic malignancies like leukemia, high-burden indications such as lung cancer, broad non-specific multi-organ cancer detection paradigms, and organ-specific targets like prostate cancer.

Based on technology, core platforms include mass spectrometry for proteomic signatures, microarray approaches for targeted genomic profiling, next-generation sequencing for comprehensive genomic and epigenomic interrogation, and polymerase chain reaction techniques for focused, high-sensitivity detection. Based on payment source, funding and access pathways vary with government subsidies that support public health initiatives, out-of-pocket payment for direct-to-consumer or elective services, and private health insurance that evaluates clinical utility and cost-effectiveness criteria. Based on application, offerings cover diagnostic screening for early detection and risk assessment, prognostic uses such as patient monitoring, therapy selection, and treatment efficacy assessment, and research applications including biomarker discovery and genetic research. Based on end user, deployment spans ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, each with distinct operational constraints, specimen logistics, and reporting requirements. Together, these segmentation lenses underscore the need for tailored evidence generation, commercial strategies, and implementation pathways that align with the intended use case and stakeholder expectations.

Comparative regional insights highlighting how regulatory frameworks, payer models, and healthcare infrastructure drive differentiated adoption pathways across global regions

Regional dynamics exert a pronounced influence on adoption pathways, regulatory expectations, and payer engagement for multicancer screening programs. In the Americas, mature healthcare infrastructures, active private payer markets, and strong translational research networks create an environment where commercial pilots and commercial models can advance rapidly, while regulatory oversight and reimbursement discussions focus on demonstrating clinical utility and care pathway integration. In Europe, Middle East & Africa, regulatory harmonization initiatives, variable reimbursement environments, and diverse healthcare delivery settings require adaptable evidence strategies, localized health economic models, and targeted stakeholder engagement to secure uptake.

In the Asia-Pacific region, rapid investments in sequencing capacity, growing public health screening initiatives, and expanding clinical trial activity are driving a dynamic landscape where both domestic innovators and global players pursue partnership models. Each region presents distinct operational considerations: supply chain logistics and laboratory capacity differ across geographies, payer frameworks range from public program-driven funding to mixed private-public arrangements, and clinician awareness and care pathways vary by local practice patterns. Consequently, commercial and clinical strategies must be regionally calibrated to address regulatory nuance, reimbursement pathways, and operational readiness while leveraging local research collaborations to accelerate evidence generation.

How collaboration, platform differentiation, and evidence-driven positioning are shaping competitive strategies and commercial pathways among diagnostic developers and laboratories

Competitive dynamics in the multicancer screening arena are characterized by a mix of established diagnostic manufacturers, specialized clinical laboratories, and nimble biotechnology startups pursuing differentiated scientific approaches. Many established players are expanding assay portfolios and forging partnerships with clinical networks to validate broader screening applications, while specialized laboratories are refining workflow integration and accreditation to support laboratory-developed tests with rapid iteration. Startups often focus on unique biomarker platforms, novel bioinformatics, or sample collection innovations that address specific gaps in sensitivity, specificity, or usability.

Strategic activity increasingly centers on collaboration: partnerships between technology providers and large laboratory networks enable access to diverse clinical specimens and pragmatic validation pathways, while alliances with academic centers facilitate translational studies and clinical utility evidence. In addition, contract development and manufacturing relationships help firms scale assay production, and collaborations with health systems support pilot implementations that test real-world clinical pathways. Across these dynamics, robustness of evidence, regulatory clarity, and the ability to integrate into clinical workflows remain primary differentiators that influence adoption trajectories and commercial positioning.

Practical, evidence-focused recommendations for developers, laboratories, and health systems to accelerate credible adoption and operational resilience in multicancer screening

Industry leaders can accelerate responsible adoption of multicancer screening by aligning product development with clear clinical use cases, prioritizing analytic rigor, and engaging early with payers and providers. First, define targeted clinical pathways that specify how a positive screening result will be triaged, what confirmatory diagnostics are required, and how follow-up care will be coordinated; clarity on downstream actions strengthens clinical utility arguments. Second, invest in analytical validation and reproducibility across diverse specimen types and demographic cohorts to reduce variability and build clinician confidence. Third, initiate payer dialogues early and develop health economic models that reflect realistic care pathways and patient journeys to inform reimbursement negotiations.

Operationally, leaders should pursue supply chain diversification and quality-controlled manufacturing to mitigate tariff and logistics risks while ensuring consistent test availability. In parallel, prioritize interoperable reporting formats and EHR integration to facilitate clinical decision support and reduce friction in provider workflows. From a commercialization perspective, pilot programs with integrated care partners, accompanied by pragmatic outcome measurement, provide actionable evidence that accelerates adoption. Finally, cultivate transparent communication with regulators and clinical societies to align on evidence thresholds and appropriate use cases, enabling scalable and clinically responsible deployment.

A rigorous mixed-methods research framework combining expert interviews, peer-reviewed evidence, regulatory review, and data triangulation to validate multicancer screening insights

The research approach combined multi-source evidence collection, expert validation, and iterative synthesis to produce balanced, actionable insights. Primary research included structured interviews with clinicians, laboratory directors, health economists, and payers to capture operational constraints, evidence expectations, and decision drivers across clinical settings. Secondary research drew on peer-reviewed literature, clinical trial registries, regulatory filings, and publicly available guidance from health technology assessment bodies to map technological capabilities and policy trends. Data triangulation was used to reconcile differing perspectives and to identify consistent signals across sources.

Analytical rigor was ensured by cross-checking technical claims against independent validation studies and by assessing operational feasibility through conversations with laboratory operators and supply chain experts. Key limitations and evidence gaps were explicitly characterized to inform future research priorities. Throughout the methodology, ethical considerations and data privacy practices guided the handling of any proprietary or patient-level information, and quality assurance steps were applied to maintain accuracy and credibility in the synthesis of findings.

Concluding synthesis emphasizing evidence alignment, operational readiness, and multi-stakeholder collaboration as prerequisites for responsible multicancer screening adoption

Multicancer screening is at an inflection point where technical maturity, clinical integration needs, and evolving payer perspectives converge to shape near-term trajectories. While technological advances are enabling broader and less invasive detection capabilities, sustainable adoption depends on demonstrable clinical pathways, interoperable reporting, and aligned reimbursement approaches. Stakeholders that pursue clear use case definition, robust validation across diverse cohorts, and pragmatic collaborations with care networks will be best positioned to translate innovation into measurable clinical benefit.

Looking ahead, the focus will be on closing evidence gaps around clinical utility, refining operational models to support scalable testing, and building resilient supply chains that accommodate changing trade and procurement landscapes. By emphasizing transparency in performance, fostering multi-stakeholder engagement, and investing in interoperable systems, the field can progress toward screening programs that deliver earlier detection, more personalized care, and improved outcomes for patients while ensuring sustainable implementation within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multicancer Screening Market, by Test Type

  • 8.1. Gene Panel
  • 8.2. Laboratory Developed Test
  • 8.3. Liquid Biopsy

9. Multicancer Screening Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Leukemia
  • 9.4. Lung Cancer
  • 9.5. Non-Specific Multi-Organ Cancer
  • 9.6. Prostate Cancer

10. Multicancer Screening Market, by Technology

  • 10.1. Mass Spectrometry
  • 10.2. Microarray
  • 10.3. Next - Generation Sequencing
  • 10.4. Polymerase Chain Reaction

11. Multicancer Screening Market, by Payment Source

  • 11.1. Government Subsidies
  • 11.2. Out-of-Pocket Payment
  • 11.3. Private Health Insurance

12. Multicancer Screening Market, by Application

  • 12.1. Diagnostic Screening
    • 12.1.1. Early Detection
    • 12.1.2. Risk Assessment
  • 12.2. Prognostics
    • 12.2.1. Patient Monitoring
    • 12.2.2. Therapy Selection
    • 12.2.3. Treatment Efficacy Assessment
  • 12.3. Research Applications
    • 12.3.1. Biomarker Discovery
    • 12.3.2. Genetic Research

13. Multicancer Screening Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Centers
  • 13.3. Hospitals
  • 13.4. Research Institutions
  • 13.5. Specialty Clinics

14. Multicancer Screening Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Multicancer Screening Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Multicancer Screening Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Multicancer Screening Market

18. China Multicancer Screening Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ANPAC Bio-Medical Science Co., Ltd.
  • 19.6. Burning Rock Biotech Limited
  • 19.7. Caris Life Sciences
  • 19.8. Coyne Medical Ltd.
  • 19.9. Delfi Diagnostics, Inc.
  • 19.10. Elypta AB
  • 19.11. EpiCypher, Inc.
  • 19.12. Epigenomics AG
  • 19.13. Exact Sciences Corporation
  • 19.14. Foundation Medicine, Inc.
  • 19.15. Freenome Holdings, Inc.
  • 19.16. Fulgent Genetics, Inc.
  • 19.17. Gene Solutions
  • 19.18. Grail, LLC by Illumina, Inc.
  • 19.19. Guangzhou AnchorDx Medical Co., Ltd.
  • 19.20. Guardant Health, Inc.
  • 19.21. Invitae Corporation
  • 19.22. Laboratory Corporation of America Holdings
  • 19.23. Lucence Health Inc.
  • 19.24. Micronoma, Inc.
  • 19.25. MiRXES Pte Ltd.
  • 19.26. Myriad Genetics, Inc.
  • 19.27. Natera, Inc.
  • 19.28. Naveris, Inc.
  • 19.29. NeoGenomics Laboratories
  • 19.30. OneTest
  • 19.31. Siemens Healthineers AG
  • 19.32. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. GCC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. G7 MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. G7 MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. G7 MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA MULTICANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)